Accelerated Approval for Neoadjuvant Chemotherapy in Breast Cancer

The FDA has recently released a draft ‘Guidance to Industry’, outlining a pathway to accelerate the approval for newer chemotherapy drugs to be used as neoadjuvant therapies and seeking public comments on the use of ‘pathological complete response’ as an end point for this approval.

Neoadjuvant treatment for cancer is the chemotherapy or radiotherapy that a patient receives before definitive treatment like surgery. The addition of a pretreatment to surgery often results in better outcomes and lowers the chances of recurrence of the cancer following surgery.

Breast Cancer - Causes, Risks, Symptoms, Diagnosis, Staging, Treatment, Prevention & Prognosis
Breast cancer is a cancer that affects the breasts or mammary glands. Early detection and lifestyle changes help in controlling breast cancer.

A new drug to treat breast cancer is first tried out in patients with metastatic disease i.e. cancer that has spread to other organs. It is available for patients with early-stage disease only after years of clinical trials. The drawback of this approach is that many patients miss the benefits of these new treatments. On the other hand, starting these drugs that have not undergone adequate clinical testing for safety may pose some risks in the form of side effects to the patient.

Taking the benefits and the possible disadvantages of using these chemotherapy drugs early, it has been suggested that these drugs could probably be tested first in those women with breast cancer who are more likely to have recurrence of the cancer following usual treatment. This includes women with high-grade tumors that are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (these cancers are referred to as triple negative).

For such newer drugs, the manufacturer should be able to demonstrate that treatment with the new drug has eradicated cancer to the point where there is no indication of cancer in the breast or lymph nodes; this is referred to as a ‘pathologic complete response’. Researchers suggested that chemotherapy drugs likely to produce a pathologic complete response should be granted accelerated approval.

Simple Device To Detect Breast Cancer Earlier Than Mammography Developed
A simple and cost effective imaging device for breast tumor detection based on a flexible and wearable antenna system has been developed by Indian origin researchers.

The new drug could be added to an existing regimen and its benefits when used with the current regimen can be first demonstrated. Continued follow up would provide efficacy and safety data over a prolonged duration. If the patient is disease free over this period, then full approval may be granted. If the manufacturer is unable to establish the benefit, the additional indication may be withdrawn.

This process of accelerated approval would benefit the numerous women who are at a risk of recurrence of breast cancer following breast cancer surgery.

Quiz on Breast Cancer
Breast cancer is one of the leading causes of cancer deaths among women. It is often said that a woman who breast-feeds is at a lower risk of developing cancer compared to another who does not .Are these mere old wives tales or is there some truth in it? This quiz on breast cancer has all the details.

Reference:

Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer; Tatiana et al; N Engl J Med 2012; 366:2438-2441

New Drug That Prevents Spread of Breast Cancer Cells and Regenerates Nerve Cells Developed
A new drug that can prevent breast cancer cells from spreading and which also led to growth of early nerve cells, known as neurites, has been developed by researchers.

Source-Medindia